Navigation Links
Lilly Reports Second-Quarter 2011 Results
Date:7/21/2011

many of our marketed products, as well as important investments we are making to expand our commercial opportunities and deliver the next wave of potential new medicines to patients," said John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer. "Key Lilly products continue to perform well, including Cymbalta, Cialis and our insulins. Exchange rates have also contributed to favorable sales comparisons. At the same time, we are investing for the company's future by supporting the launches of new medicines and new indications, as well as funding our R&D pipeline, which now boasts 70 potential new medicines in clinical development."

Key Events Over the Last Three Months

  • The U.S. Food and Drug Administration (FDA) approved Tradjenta™ (linagliptin), a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. The company, along with its partner Boehringer Ingelheim, recently launched Tradjenta in the United States. Linagliptin was also approved in Japan, Mexico and Brazil and received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
  • The European Commission granted marketing authorization to Bydureon™, the first once-weekly treatment for type 2 diabetes. The company is developing Bydureon along with its partners, Amylin Pharmaceuticals and Alkermes, Inc.
  • The company filed for a new indication with the FDA for Erbitux® in first-line non-small cell lung cancer.
  • The U.S. District Court for the Southern District of Indiana issued an order that prohibits the remaining defendants in the Cymbalta® patent litigation from selling a generic duloxetine product in the United States during the term of the Cymbalta compound patent. The patent provides protection for Cymbalta until at least June of 2013.  
  • The company signed agreements with private investors Care Capit
    '/>"/>

  • SOURCE Eli Lilly and Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimers Disease Research
    2. Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lillys Beamline Capabilities
    3. Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer
    4. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
    5. Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System
    6. Lilly Quality Leader Walsh Appointed to Companys Executive Committee
    7. Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations
    8. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
    9. Lilly Declares Third-Quarter 2011 Dividend
    10. Lilly for Better Healthâ„¢ Launches Enhanced Multi-Channel Patient Education Platform
    11. Synthes and Lilly Sign Development and Collaboration Agreement
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/2/2014)...   West Pharmaceutical Services, Inc. (NYSE: ... for injectable drug administration, announced today it plans to ... site in Waterford, Ireland . The ... cartridges and other high-value packaging components, in order to ... operational, this new site could bring approximately 150 new ...
    (Date:10/1/2014)... , Oct. 1, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care instruments and consumables for the medical, research, and ... the veterinary and research markets in the ... into a definitive distribution agreement with Patterson Veterinary Supply. ... promote the full line of Abaxis veterinary products throughout ...
    (Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, Inc. ... patented and proprietary technology used to develop and ... bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, today ... from Abengoa Bioenergy for commercial scale production of ... into ethanol, developed under Abengoa,s license agreement with ...
    Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
    ... a developer of Healthcare Technology Networks ("HTN") designed to ... today announces the launch of its proprietary Opioid Management ... United States Bone & Joint Decade , ... suffering from musculoskeletal disease filled 1.6 billion prescriptions. While ...
    ... SPRING, Md., April 6, 2012 Sunpeaks Ventures, ... "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution ... has entered into a sponsorship agreement ("Agreement") with a ... Clotamin, including advertising, media, and promotional elements. The Agreement ...
    Cached Medicine Technology:Med-Tek Launches the First Evidenced Based Opioid Management Program (OMP) 2Sunpeaks Ventures Inks Sponsorship and Marketing Agreement with Major Sports Team, Clotamin To Be Sold at Walgreens Locations Throughout Oregon and Southern Washington 2Sunpeaks Ventures Inks Sponsorship and Marketing Agreement with Major Sports Team, Clotamin To Be Sold at Walgreens Locations Throughout Oregon and Southern Washington 3
    (Date:10/2/2014)... Norton HealthDay Reporter WEDNESDAY, Oct. ... the roses -- literally -- may face an increased risk of ... a study of over 3,000 older Americans, researchers found those who ... were more than three times as likely to die in the ... In fact, anosmia -- the inability to distinguish odors -- ...
    (Date:10/2/2014)... at The University of Nottingham could lead to the ... A drug resulting from the research, published in the ... hope to sufferers of chronic pain conditions such as ... currently available. , The work, led by Dr Lucy ... collaboration with David Bates, Professor of Oncology in the ...
    (Date:10/1/2014)... shown that more than 80 per cent of bowel ... study found that medicines called ,JAK inhibitors, halted tumour ... is present in more than 80 per cent of ... are in clinical trials, for diseases including rheumatoid arthritis, ... is the second-most common cancer in Australia with nearly ...
    (Date:10/1/2014)... co-funded by the Engineering and Physical Sciences Research ... the UK,s vital industrial control systems which run, ... grid, and the rail network. , The ... hackers or malware infiltrating the systems behind our ... in Trustworthy Industrial Control Systems (RITICS), based at ...
    (Date:10/1/2014)... the adage that encourages people to keep their "eyes ... comes to exercise. When walking, staying focused on a ... appear shorter and help people walk there faster, psychology ... to walking while looking around the environment naturally, offers ... , "People are less interested in exercise if physical ...
    Breaking Medicine News(10 mins):Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Medical discovery first step on path to new painkillers 2Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
    ... novel study found that the use of Herceptin in advanced ... toxicity − nearly 28 percent of patients treated with ... lining is that much of the damage to the heart ... published online August 14 in the Journal of Clinical Oncology, ...
    ... OHSU Tinnitus Clinic and the School of Dentistry is ... their relationship with hearing loss//. Apparently the relationship has ... of the study leaders, said"Over the years, we have ... convinced that long-term exposure to sound from high-speed hand ...
    ... The three-hour open-heart surgery was performed on a 17 yr ... ,An eight-member team led by cardio thoracic surgeon ... suffering from an arterial septal, congenital defect on the 4th ... of TMCH said that the patient, S.Velumurugan's condition was stable ...
    ... from the US have shown that yellow plant pigments ... macular degeneration (AMD). ,The study conducted by the ... published in the Journal of Ophthalmology, states that carrots ... but brightly coloured yellow and green vegetables do have ...
    ... Most women who undergo surgery following an early pregnancy ... under general ,anesthesia//. However a new study has raised ... ,Early pregnancy failure - or EPF - occurs in ... with surgery typically haven't been performed in ,an office-based ...
    ... of a fourth drug to the usual three-drug HIV treatment ... did not reduce the HIV load// or the drug resistance, ... 16 issue of JAMA, a theme issue on HIV/AIDS. ... of Cornell University, New York, presented the findings of the ...
    Cached Medicine News:Health News:Herceptin Use May Enhance Cardiac Toxicity, Study 2Health News:Herceptin Use May Enhance Cardiac Toxicity, Study 3Health News:Is There a Connection between Hearing loss and High-speed Dental Tools? 2Health News:Is There a Connection between Hearing loss and High-speed Dental Tools? 3Health News:Yellow Fruits And Vegetables Help In Fight Against Loss Of Eyesight 2Health News:Women Prefer Office Procedure during treatment of Early Pregnancy 2Health News:Women Prefer Office Procedure during treatment of Early Pregnancy 3Health News:Four-Drug AIDS Treatment Regimen Deemed Of No Use 2
    AST (SGOT) R1 + R2. Automated analyzer test kits....
    Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
    The Midas II Stainer is an automated slide stainer designed for use in hematology and microbiology laboratories....
    ... TST 40 tissue stainer is an "assembly-line ... in histology and cytology laboratories. Programmable continuous ... stains big quantities of slides in short ... in combination with a continuous working principle ...
    Medicine Products: